Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) - Volume 14, Issue 2, 2016

Background: Many drugs when conjugated with DNA by covalent or noncovalent interaction form highly reactive, site specific delivery species called drug-DNA adduct. Objective: The objective of the present review is to highlight the importance and utility of DNA – drug conjugates for site-specific delivery in anti-cancer therapy. Results: Drugs, such as doxorubicin, cisplatin, ellipticine, melphalan, tamoxifen, etc. were reacte Read More

Background: Genomic basis of drug response is the main objective of Pharmacogenomic studies. The classical paradigm of clinical treatment focused in the disease is becoming a new approach, the Personalized Medicine (PM) based on the individual patient. One important challenge of PM application is the availability of adequate and validated genetic information. Objective: In this review, we will focus on the impact of new Read More

Background: A typical feature of acute myeloid leukemia (AML) consists in the blockade of the cell differentiation process. Many experimental studies have shown that some chemical compounds induce the selective differentiation of hematopoietic cell lines, thus supporting the rationale of using these agents to treat AML by forcing these cells to undergo a process of terminal differentiation. From these studies emerged the Read More

Background: MicroRNAs are non-coding RNAs which regulate gene expression by binding to 3’ UTR site on mRNA. These small RNAs repress gene expression by interfering with the process of translation or by degrading the target mRNA. Abnormal expression of miRNAs has been implicated in a wide spectrum of human diseases like atherosclerosis, cancers and diabetes. Traditionally, pharmacogenomics focuses on single nucle Read More

Background: By using exome sequencing, we envisioned that certain single nucleotide variants (SNVs), predictive of sensitivity to platinum treatment, could be discovered. Methods: Twenty-two Platinum-Sensitive (Pt-S) and 6 Platinum-Resistant (Pt-R) ovarian cancer patients were tested. Platinum sensitivity was defined as disease free survival greater than 6 months. Next-generation sequencing of exomes was used to co Read More